|Year : 2015 | Volume
| Issue : 5 | Page : 163-164
Mucor -culture/molecular analysis necessary for identification
S Duggal, SR Rongpharpi
Department of Microbiology, Dr. Baba Saheb Ambedkar Hospital, Rohini, Delhi, India
|Date of Submission||27-May-2014|
|Date of Acceptance||09-Oct-2014|
|Date of Web Publication||6-Feb-2015|
Department of Microbiology, Dr. Baba Saheb Ambedkar Hospital, Rohini, Delhi
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Duggal S, Rongpharpi S R. Mucor -culture/molecular analysis necessary for identification. Indian J Med Microbiol 2015;33, Suppl S1:163-4
|How to cite this URL:|
Duggal S, Rongpharpi S R. Mucor -culture/molecular analysis necessary for identification. Indian J Med Microbiol [serial online] 2015 [cited 2020 Apr 9];33, Suppl S1:163-4. Available from: http://www.ijmm.org/text.asp?2015/33/5/163/150960
This is with reference to a case report by Angeline, et al.,  'Subcutaneous Mucor Zygomycosis with potential life threatening visceral complication', published in the Indian J Med Microbiol 2013;31 (2):182-4. We have some reservations regarding use of the word 'Mucor' in the title.
The authors have described a case of subcutaneous zygomycosis. Taxonomic organisation of zygomycetes has been described in a review by Ribes et al.,  and in greater detail by Hoffman et al.  Mucor is one of the 57 genera of the order-Mucorales of the phylum Zygomycota. 
The findings in the case report included involvement of subcutaneous site and presence of eosinophilic granuloma that is Splendore Hoeppli phenomenon. These findings are commonly seen in infections due to Entomophthorales but rarely with Mucorales. Response to fluconazole therapy has been described before for Entomophthorales whereas resistance has been reported consistently against Mucorales. Though the patient responded to fluconazole therapy and the authors have described it as an exception; in the absence of a culture report or molecular analysis, it may not be appropriate to label it as a case of 'Mucor' or 'Mucorales' as it may prompt the readers to use fluconazole for the treatment of other 'Mucor' infections.
| ~ References|| |
Angeline, Hanifah M, Balachandran G, Rajesh NG. Subcutaneous mucor zygomycosis with potential life-threatening visceral complication. Indian J Med Microbiol 2013;31:182-4.
Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000;13:236-301.
Hoffman K, Pawlowska J, Walther G, Wrzosek M, de Hoog GS, Benny GL, et al
. The family structure of the Mucorales: A synoptic revision based on comprehensive multigene-genealogies. Persoonia 2013;30:57-76.
Gugnani HC, Ezeanolue BC, Khalil M, Amoah CD, Ajuiu EU, Oyewo EA. Fluconazole in the therapy of tropical deep mycoses. Mycoses 1995;38:485-8.
Kanafani ZA, Perfect JR. Antimicrobial resistance: Resistance to antifungal agents: Mechanisms and clinical impact. Clin Infect Dis 2008;46:120-8.